Whistler Conference Centre Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2011
Here are the related meetings in 2021:
Next Generation HIV Vaccines & Therapies - RESCHEDULING IN PROGRESS (B4)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Protection from HIV: Targeted Intervention Strategies (X8)
Organizer(s) Mario Roederer, Carolyn Williamson and Robin Shattock
March 20—25, 2011
Whistler Conference Centre • Whistler, BC Canada
Abstract Deadline: Nov 22, 2010
Late Abstract Deadline: Dec 22, 2010
Scholarship Deadline: Nov 22, 2010
Early Registration Deadline: Jan 21, 2011
Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation. Sponsored by Sangamo BioSciences, Inc.
Joint Meeting:
HIV Evolution, Genomics and Pathogenesis (X7)
Summary of Meeting:
Biological efforts to prevent HIV infection center on four independent approaches: inducing adaptive immune responses through vaccination, augmenting innate responses, using peri-exposure prophylactic drug therapy, and developing microbicides and/or recombinant antiviral microbial products. While all four of these approaches have promise, they still require significant optimization and further clinical trials. Indeed, successful prevention of HIV infection will likely require a combination of these approaches. Such development efforts require a better understanding of viral and immunological events at the site of transmission. This Keystone Symposia meeting will have a focus on mucosal immunology as well as the interplay between the virus and innate and adaptive immune responses, particularly during the acute phase of the infection. Leading experts in the fields will discuss recent scientific advances in these varied approaches to preventing infection and present data from recent clinical trials testing their efficacy.
View Scholarships/Awards
Biological efforts to prevent HIV infection center on four independent approaches: inducing adaptive immune responses through vaccination, augmenting innate responses, using peri-exposure prophylactic drug therapy, and developing microbicides and/or recombinant antiviral microbial products. While all four of these approaches have promise, they still require significant optimization and further clinical trials. Indeed, successful prevention of HIV infection will likely require a combination of these approaches. Such development efforts require a better understanding of viral and immunological events at the site of transmission. This Keystone Symposia meeting will have a focus on mucosal immunology as well as the interplay between the virus and innate and adaptive immune responses, particularly during the acute phase of the infection. Leading experts in the fields will discuss recent scientific advances in these varied approaches to preventing infection and present data from recent clinical trials testing their efficacy.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MARCH 20
MONDAY, MARCH 21
TUESDAY, MARCH 22
WEDNESDAY, MARCH 23
THURSDAY, MARCH 24
FRIDAY, MARCH 25
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, MARCH 20
19:15—20:30
Welcome and Keynote Address: Viral Transmission Dynamics (Joint)
Ashley T. Haase,
University of Minnesota, USA
Founder Events at the Portal of Entry in Mucosal Transmission
Founder Events at the Portal of Entry in Mucosal Transmission
08:00—11:00
Virus-Specific Microbicides
*
Robin Shattock,
Imperial College London, UK
Peter A. Anton,
David Geffen School of Medicine at UCLA, USA
Rectal Microbicides: Mucosal Lessons in Developing New Therapies
Rectal Microbicides: Mucosal Lessons in Developing New Therapies
Laurel A. Lagenaur,
Osel Inc., USA
“Live” Microbial Prevention Strategies
“Live” Microbial Prevention Strategies
Oliver Hartley,
University of Geneva, Switzerland
Targeting CCR5 in HIV Prevention
Targeting CCR5 in HIV Prevention
Walid Heneine,
Centers for Disease Control and Prevention, USA
Prevention of SHIV Infection in Macaques by Oral and Topical Antiretroviral Prophylaxis
Prevention of SHIV Infection in Macaques by Oral and Topical Antiretroviral Prophylaxis
Nathalie Dereuddre-Bosquet,
Commissariat à l'Energie Atomique, France
Short Talk: MiniCD4 Microbicide Gel Prevents Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques
Short Talk: MiniCD4 Microbicide Gel Prevents Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques
08:00—11:00
Lentiviral Diversity
Aris Katzourakis,
University of Oxford, UK
Endogenous Retroviruses and the Evolution of the Lentiviruses
Endogenous Retroviruses and the Evolution of the Lentiviruses
Michael Worobey,
University of Arizona, USA
The Tempo and Mode of SIV and HIV Outbreaks
The Tempo and Mode of SIV and HIV Outbreaks
Frederic Bibollet-Ruche,
University of Pennsylvania, USA
Short Talk: A Chimpanzee CD4 Glycosylation Site Polymorphism Governs Susceptibility to SIVcpz Infection
Short Talk: A Chimpanzee CD4 Glycosylation Site Polymorphism Governs Susceptibility to SIVcpz Infection
Will Fischer,
Los Alamos National Laboratory, USA
Short Talk: Whole-Genome Deep-Sequencing of HIV-1 in the First Weeks, Months, and Years of Infection
Short Talk: Whole-Genome Deep-Sequencing of HIV-1 in the First Weeks, Months, and Years of Infection
11:00—12:30
Hands-On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
11:00—12:30
Hands On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
14:30—16:30
Workshop 1: Vaccines & Immune Responses
Shan Lu,
University of Massachusetts Medical Center, USA
Identification of a Subset of Primary HIV-1 Env that can Elicit Broader Neutralizing Antibody Responses by a DNA Prime – Protein Boost Vaccination Strategy
Identification of a Subset of Primary HIV-1 Env that can Elicit Broader Neutralizing Antibody Responses by a DNA Prime – Protein Boost Vaccination Strategy
David B. Weiner,
Wistar Institute, USA
Enhanced DNA Vaccine +/-Protein Boost Delivered by EP Expands B and T Cell Responses and Neutralizing Phenotype in vivo
Enhanced DNA Vaccine +/-Protein Boost Delivered by EP Expands B and T Cell Responses and Neutralizing Phenotype in vivo
Penny L. Moore,
University of the Witwatersrand and National Institute for Communicable Diseases, South Africa
Development of Broadly Cross-Neutralizing Antibodies is Associated with Delayed HIV Viral Escape
Development of Broadly Cross-Neutralizing Antibodies is Associated with Delayed HIV Viral Escape
Matthew Johnson,
National Institutes of Health, USA
Determinants of Poor Immunogenicity of Alternative Adenoviruses
Determinants of Poor Immunogenicity of Alternative Adenoviruses
Jeffrey Teigler,
US Military HIV Research Program, USA
Cytokine Secretion Profiles of Adenovirus and Poxvirus Vaccine Vectors in Rhesus Macaques
Cytokine Secretion Profiles of Adenovirus and Poxvirus Vaccine Vectors in Rhesus Macaques
Michael K.P. Liu,
University of Oxford, UK
The Role of The First/Early T Cells In Subjects With Acute HIV-1 Infection
The Role of The First/Early T Cells In Subjects With Acute HIV-1 Infection
14:30—16:30
Workshop 1: Innate Immune Sensing of Lentiviruses
Richard M. Dunham,
ViiV Healthcare, USA
TLR-Mediated IFNalpha and IDO Production in pDC is Altered in African Green Monkeys
TLR-Mediated IFNalpha and IDO Production in pDC is Altered in African Green Monkeys
Anna Aldovini,
Boston Children's Hospital and Harvard Medical School, USA
HIV-1 Tat Mimics the Activity of Interferons in Primary Human Immature Dendritic Cells and Macrophages
HIV-1 Tat Mimics the Activity of Interferons in Primary Human Immature Dendritic Cells and Macrophages
Susanna Marie Bächle,
Karolinska Institutet, Sweden
Evolutionary Conservation of Lentiviral Interference with CD1d-Mediated Immunity
Evolutionary Conservation of Lentiviral Interference with CD1d-Mediated Immunity
Edward Barker,
Rush University Medical Center, USA
Vpu Prevents Natural Killer Cell Destruction of HIV-Infected Cells
Vpu Prevents Natural Killer Cell Destruction of HIV-Infected Cells
Mario L. Santiago,
University of Colorado Denver, USA
Mechanistic Dissection of the Apobec3/Rfv3 Phenotype: Implications for Improving Retroviral Humoral Immunity
Mechanistic Dissection of the Apobec3/Rfv3 Phenotype: Implications for Improving Retroviral Humoral Immunity
17:00—19:00
Clinical Trials Update
*
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Myron S. Cohen,
University of North Carolina at Chapel Hill, USA
Antiretroviral Therapy to Prevent HIV-1: Before and After the(F)Act(s)
Antiretroviral Therapy to Prevent HIV-1: Before and After the(F)Act(s)
Nelson L. Michael,
Walter Reed Army Institute of Research, USA
Beyond RV 144: Prime Boost Approaches
Beyond RV 144: Prime Boost Approaches
Salim S. Abdool Karim,
University of KwaZulu-Natal, South Africa
Update on Microbicide and Pre-exposure Prophylaxis (PrEP) Trials
Update on Microbicide and Pre-exposure Prophylaxis (PrEP) Trials
17:00—19:00
Non-Pathogenic Lentiviral Infections
Theodora Hatziioannou,
Aaron Diamond AIDS Research Center, USA
Towards an animal model for HIV/AIDS
Towards an animal model for HIV/AIDS
Cristian Apetrei,
University of Pittsburgh, USA
Pathogenesis of Cross-Species-Transmitted SIV Infection
Pathogenesis of Cross-Species-Transmitted SIV Infection
Michaela Müller-Trutwin,
Institut Pasteur, France
IFN-I related Responses in Non-pathogenic Versus Pathogenic SIV/HIV Infections
IFN-I related Responses in Non-pathogenic Versus Pathogenic SIV/HIV Infections
Jacob D. Estes,
Oregon Health and Science University, USA
Short Talk: Reduced Lymphatic Tissue Immunopathology and Altered Myeloid Lineage Cell Recruitment in SIV-Infected Rhesus Macaques Receiving Anti-TNFalpha Treatment
Short Talk: Reduced Lymphatic Tissue Immunopathology and Altered Myeloid Lineage Cell Recruitment in SIV-Infected Rhesus Macaques Receiving Anti-TNFalpha Treatment
08:00—11:15
Correlates of Protection
*
Eric Hunter†,
Emory University, USA
Jo-Ann S. Passmore,
University of Cape Town, South Africa
Correlates of Protection against HIV Infection in the Female Genital Tract
Correlates of Protection against HIV Infection in the Female Genital Tract
Susan W. Barnett,
Bill & Melinda Gates Foundation, USA
Protective Vaccine-Induced Humoral Responses
Protective Vaccine-Induced Humoral Responses
Anuradha Ganesan,
Anuradha Ganesan, USA
Early Immunologic and Virologic Correlates of Protection
Early Immunologic and Virologic Correlates of Protection
Ravi Tandon,
John A. Burns School of Medicine, University of Hawai'i, USA
Short Talk: HERV Specific T Cell Responses in Vertically HIV-1 Infected Children are Inversely Correlated with HIV-1 Plasma Viral Load
Short Talk: HERV Specific T Cell Responses in Vertically HIV-1 Infected Children are Inversely Correlated with HIV-1 Plasma Viral Load
Monica Vaccari,
NCI, National Institutes of Health, USA
Short Talk: Efficacy of HIV Vaccine Candidate in Macaques Dependent on the Dose of SIVmac251 Challenge Exposure
Short Talk: Efficacy of HIV Vaccine Candidate in Macaques Dependent on the Dose of SIVmac251 Challenge Exposure
M. Juliana McElrath,
Fred Hutchinson Cancer Research Center, USA
Cellular Immune Responses Induced by HIV Vaccines
Cellular Immune Responses Induced by HIV Vaccines
08:00—11:00
Evolution of Pathogenicity
*
Cristian Apetrei,
University of Pittsburgh, USA
Guido Silvestri,
Emory University School of Medicine, USA
Protection of Central Memory CD4+ T Cell Homeostasis in Natural SIV Hosts
Protection of Central Memory CD4+ T Cell Homeostasis in Natural SIV Hosts
Michael Emerman,
Fred Hutchinson Cancer Research Center, USA
Paleovirology and the Evolution of Primate Antiviral Defenses
Paleovirology and the Evolution of Primate Antiviral Defenses
Sebastian L. Bonhoeffer,
ETH-Zentrum, Switzerland
Tracing Epidemiological Patterns in Sequence Data: Transmission Structure, Basic Reproductive Rate, and Heritability of Virus Load
Tracing Epidemiological Patterns in Sequence Data: Transmission Structure, Basic Reproductive Rate, and Heritability of Virus Load
Nichole R. Klatt,
University of Miami, USA
Short Talk: Mechanisms Underlying Damage to the Mucosal Barrier and Immune Activation after Pathogenic SIV Infection of Rhesus Macaques
Short Talk: Mechanisms Underlying Damage to the Mucosal Barrier and Immune Activation after Pathogenic SIV Infection of Rhesus Macaques
11:15—12:30
Hands On Computer Workshop on Los Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
11:15—12:30
Hands On Computer Workshop on Los Alamos Sequence Database
Maximum attendance: 60. Interested participants may sign up at the meeting on a first-come, first-serve basis.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
Instructors: Brian Foley, Karina Yusim, Will Fischer.
14:30—16:30
Workshop 2: Mucosal Immunology and Microbicides
*
Jo-Ann S. Passmore,
University of Cape Town, South Africa
Carolina Herrera,
Imperial College, UK
Combinations of Maraviroc and Reverse Transcriptase Inhibitors as Potential Microbicides
Combinations of Maraviroc and Reverse Transcriptase Inhibitors as Potential Microbicides
Peter D. Katsikis,
Drexel University College of Medicine, USA
Anti-Viral and Anti-Inflammatory Dual Acting Microbicide for HIV-1 Infection
Anti-Viral and Anti-Inflammatory Dual Acting Microbicide for HIV-1 Infection
Ramesh K. Akkina,
Colorado State University, USA
Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model
Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model
Jean-Charles J. B. Grivel,
Sidra Medical and Research Center, Qatar
Infection of Cervical Tissue Explants with Transmitted/Founder HIV-1 Viruses
Infection of Cervical Tissue Explants with Transmitted/Founder HIV-1 Viruses
Steven L. Zeichner,
University of Virginia, USA
HIV Human Vaginal Microbicide Effects on the Vaginal Microbial Community
HIV Human Vaginal Microbicide Effects on the Vaginal Microbial Community
Natasa Strbo,
School of Medicine, University of Miami, USA
Profound Mucosal CD8+ T Cell Immunity Elicited by Intraperitoneal Immunization with Secreted Heat Shock Protein gp96-Ig
Profound Mucosal CD8+ T Cell Immunity Elicited by Intraperitoneal Immunization with Secreted Heat Shock Protein gp96-Ig
17:00—19:00
Viral Variation from Transmission to Populations (Joint)
*
Michael Worobey,
University of Arizona, USA
Carolyn Williamson,
University of Cape Town, South Africa
Early Viral Evolution and Escape in Subtype C Infected Individuals with Single- and Super-Infection
Early Viral Evolution and Escape in Subtype C Infected Individuals with Single- and Super-Infection
Jessica L. Prince,
Emory University, USA
Short Talk: The Role of Transmitted HLA Associated Gag Polymorphisms in Defining HIV-1 Set-Point Viral Load and in vitro Replicative Fitness
Short Talk: The Role of Transmitted HLA Associated Gag Polymorphisms in Defining HIV-1 Set-Point Viral Load and in vitro Replicative Fitness
Brandon F. Keele,
Frederick National Laboratory, USA
Modeling HIV Transmission and Early Evolution in Nonhuman Primates
Modeling HIV Transmission and Early Evolution in Nonhuman Primates
08:00—11:15
Humoral Responses
Peter D. Kwong,
NIAID, National Institutes of Health, USA
Prospects for Generating VRC01-like Antibodies Revealed by Crystal Structures and 454 Pyrosequencing
Prospects for Generating VRC01-like Antibodies Revealed by Crystal Structures and 454 Pyrosequencing
John R. Mascola,
NIAID, National Institutes of Health, USA
Isolation and Characterization of Broadly Neutralizing Monoclonal Antibodies to HIV-1
Isolation and Characterization of Broadly Neutralizing Monoclonal Antibodies to HIV-1
Nancy L. Haigwood,
Oregon Health & Science University, USA
Short Talk: Passive Transfer of Physiologic Levels of Neutralizing IgG Results in Profound Control of Plasma Virus in Newborn Rhesus Macaques Orally Exposed to SHIV-SF162P3 and Protects B Cells in vivo
Short Talk: Passive Transfer of Physiologic Levels of Neutralizing IgG Results in Profound Control of Plasma Virus in Newborn Rhesus Macaques Orally Exposed to SHIV-SF162P3 and Protects B Cells in vivo
Shannon A. Allen,
Northwestern University Feinberg School of Medicine, USA
Short Talk: Neutralizing and Non-Neutralizing HIV-Specific Antibodies Hinder the Movement of Virus in Fresh Human Cervical Mucus
Short Talk: Neutralizing and Non-Neutralizing HIV-Specific Antibodies Hinder the Movement of Virus in Fresh Human Cervical Mucus
Lynn Morris,
National Institute for Communicable Diseases, South Africa
Interplay between Autologous and Broadly Cross-Reactive Neutralizing Antibodies in HIV-1 Infection
Interplay between Autologous and Broadly Cross-Reactive Neutralizing Antibodies in HIV-1 Infection
08:00—11:00
Host Genome I: The Variable Human Genome
David B. Goldstein,
Duke University, USA
Whole Genome Sequencing and the Host Genetics of HIV-1 Acquisition and Viral Control
Whole Genome Sequencing and the Host Genetics of HIV-1 Acquisition and Viral Control
Manolis Emmanouil T. Dermitzakis,
University of Geneva Medical School, Switzerland
Human Cellular Quantitative Genetics
Human Cellular Quantitative Genetics
Monsef Benkirane,
Institut de Genetique Humaine, France
Identification of an HIV Restriction Fsctor in DCs
Identification of an HIV Restriction Fsctor in DCs
Amalio Telenti,
Centre Hospitalier Universitaire Vaudois, Switzerland
Host and Pathogen Evolution at Genome Scale
Host and Pathogen Evolution at Genome Scale
14:30—16:30
Workshop 2: HIV/Host Interactions
*
Vicente Planelles,
University of Utah, USA
Homeostatic Proliferation of Central Memory T Cells and the Latent HIV-1 Reservoir
Homeostatic Proliferation of Central Memory T Cells and the Latent HIV-1 Reservoir
Mathias Lichterfeld,
Brigham and Women's Hospital, USA
An Intrinsic Inhibitor of CDK9-Mediated Transcriptional Elongation of HIV-1 in CD4 T Cells from Elite Controllers
An Intrinsic Inhibitor of CDK9-Mediated Transcriptional Elongation of HIV-1 in CD4 T Cells from Elite Controllers
Vincent Piguet,
Cardiff University, UK
Quantitative Multicolour Super-Resolution Microscopy Reveals Tetherin HIV-1 Interaction
Quantitative Multicolour Super-Resolution Microscopy Reveals Tetherin HIV-1 Interaction
Suzanne Willey,
Kings College London, UK
Analysis of Tetherin Antagonism by HIV-1 Vpu and HIV-2 Env Alleles Isolated from Infected Individuals
Analysis of Tetherin Antagonism by HIV-1 Vpu and HIV-2 Env Alleles Isolated from Infected Individuals
Rogier W. Sanders,
University of Amsterdam and Weill Cornell Medical College, Netherlands
HIV-1 N-Glycan Composition Governs a Balance between Dendritic Cell-Mediated Viral Transmission and Degradation
HIV-1 N-Glycan Composition Governs a Balance between Dendritic Cell-Mediated Viral Transmission and Degradation
Nuria Izquierdo-Useros,
AIDS Research Institute Irsicaixa, Spain
Live Cell Imaging of Cell-Associated Viral Capture by Mature Dendritic Cells
Live Cell Imaging of Cell-Associated Viral Capture by Mature Dendritic Cells
David R. Graham,
Johns Hopkins School of Medicine, USA
An Update on HIV Proteomics: Comparisons between Macrophage and T Cell Derived HIV-1
An Update on HIV Proteomics: Comparisons between Macrophage and T Cell Derived HIV-1
14:30—16:30
Workshop: Data Sharing: A Priority of the Enterprise 2010 Scientific Strategic Plan
*
Yegor Voronin,
Worcester HIV Vaccine, USA
*
Lynn Morris,
National Institute for Communicable Diseases, South Africa
17:00—19:00
The Earliest Responses and Host Genetics
*
Thomas J. Hope,
Northwestern University, USA
Galit Alter,
MIT and Harvard University, USA
Innate Recognition: NK Cells
Innate Recognition: NK Cells
Christian L. Boutwell,
General Hospital Corporation, USA
Short Talk: Ultra-Deep Whole Genome HIV Sequencing Reveals the Impact of Viral Adaptation on Immune Control During Acute Infection
Short Talk: Ultra-Deep Whole Genome HIV Sequencing Reveals the Impact of Viral Adaptation on Immune Control During Acute Infection
Georgia D. Tomaras,
Duke University Medical Center, USA
Analysis of the Envelope B Cell Repertoire in the Thai RV144 Efficacy Trial
Analysis of the Envelope B Cell Repertoire in the Thai RV144 Efficacy Trial
Andrew J. McMichael,
Oxford University, UK
T Cell Responses, HLA B*57 and Control of Viremia in Acute HIV-1 Infection
T Cell Responses, HLA B*57 and Control of Viremia in Acute HIV-1 Infection
17:00—19:00
Host Genome II: Host Genome and Retroviral Infection
Frederic D. Bushman,
University of Pennsylvania, USA
HIV DNA Integration and RNA Splicing Studied using Deep Sequencing
HIV DNA Integration and RNA Splicing Studied using Deep Sequencing
Angela Ciuffi,
Institute of Microbiology - CHUV/UNIL, Switzerland
Host Transcriptional Reprogramming during the HIV Life Cycle
Host Transcriptional Reprogramming during the HIV Life Cycle
Paul de Bakker,
Vertex Pharmaceuticals, USA
Unravelling the Genetic Contributions of MHC Variation to Durable Host Control of HIV-1
Unravelling the Genetic Contributions of MHC Variation to Durable Host Control of HIV-1
Nick Schopman,
University of Amsterdam, Netherlands
Short Talk: Deep Sequencing of Small RNAs from HIV-1 Infected Cells Reveals Possible HIV-Encoded miRNAs
Short Talk: Deep Sequencing of Small RNAs from HIV-1 Infected Cells Reveals Possible HIV-Encoded miRNAs
08:00—11:15
Cellular Vaccines
*
Richard A. Koup†,
NIAID, National Institutes of Health, USA
R. Paul Johnson,
Harvard Medical School, USA
Maturation of Protective Immunity Induced by Live Attenuated SIV
Maturation of Protective Immunity Induced by Live Attenuated SIV
Willem A. Hanekom,
Bill & Melinda Gates Foundation, USA
Correlates of Protection following Vaccination against TB
Correlates of Protection following Vaccination against TB
Norman L. Letvin,
Beth Israel Deaconess Medical Center, USA
Genetic Determinants of Vaccine Protection in Rhesus Monkeys
Genetic Determinants of Vaccine Protection in Rhesus Monkeys
Neil Almond,
National Institute Biology Standards, UK
Short Talk: Conditional Live Attenuated SIVrtTA Protects Against Heterologous SIVsmE660
Short Talk: Conditional Live Attenuated SIVrtTA Protects Against Heterologous SIVsmE660
Maria H. Foley,
Massachusetts Institute of Technology, USA
Short Talk: Time-Lapse Video Microscopy of HIV-Specific CTL: The Effects of Cell Motility and TCR Avidity on Target Engagement and Killing
Short Talk: Time-Lapse Video Microscopy of HIV-Specific CTL: The Effects of Cell Motility and TCR Avidity on Target Engagement and Killing
Louis J. Picker,
Oregon Health & Science University, USA
Live Vectors - CMV
Live Vectors - CMV
08:00—11:00
HIV Host Interactions
*
Theodora Hatziioannou,
Aaron Diamond AIDS Research Center, USA
Vineet N. KewalRamani,
NCI, National Institutes of Health, USA
Genetics of HIV Entry into the Nucleus
Genetics of HIV Entry into the Nucleus
Jeremy Luban,
University of Massachusetts Medical School, USA
TRIM5 is an Innate Immune Sensor for the Capsid of HIV-1 and Other Retroviruses
TRIM5 is an Innate Immune Sensor for the Capsid of HIV-1 and Other Retroviruses
Thomas J. Hope,
Northwestern University, USA
Short Talk: Reverse Transcription Facilitates HIV Uncoating
Short Talk: Reverse Transcription Facilitates HIV Uncoating
Benjamin K. Chen,
Mount Sinai School of Medicine, USA
Short Talk: Neutralization Resistance of HIV-1 Virological Synapse-Mediated Infection is Regulated by Env Cytoplasmic Tail
Short Talk: Neutralization Resistance of HIV-1 Virological Synapse-Mediated Infection is Regulated by Env Cytoplasmic Tail
14:30—16:30
Workshop 3: The NHP Model - Limitations and Lessons
*
Brandon F. Keele,
Frederick National Laboratory, USA
Thomas Lehner,
Guy's, King's & St. Thomas' Hospital Medical and Dental School, UK
A Protective Allo-Immune Strategy Utilising Serum and Mucosal Antibodies and APOBEC3G
A Protective Allo-Immune Strategy Utilising Serum and Mucosal Antibodies and APOBEC3G
Matthew R. Reynolds,
University of Wisconsin-Madison, USA
Testing the Efficacy of the STEP Trial Recombinant Ad5 gag/pol/nef Vaccine Regimen in Rhesus Macaques using a Limiting Dose Heterologous SIV Challenge
Testing the Efficacy of the STEP Trial Recombinant Ad5 gag/pol/nef Vaccine Regimen in Rhesus Macaques using a Limiting Dose Heterologous SIV Challenge
Barbara K. Felber,
NCI, National Institutes of Health, USA
SIVmac239 DNA and Virus Particle Vaccination Confers Protection Upon Mucosal Challenge With Heterologous SIVsmE660
SIVmac239 DNA and Virus Particle Vaccination Confers Protection Upon Mucosal Challenge With Heterologous SIVsmE660
Jorge Ramos de Almeida,
NIAID, National Institutes of Health, USA
CD8+ T Cell Public Clonotype Usage in a Single Epitope-Specific Response in Acute SIV Infection of Mamu-B*08 Positive Rhesus Macaques may Determine Control of Viral Replication
CD8+ T Cell Public Clonotype Usage in a Single Epitope-Specific Response in Acute SIV Infection of Mamu-B*08 Positive Rhesus Macaques may Determine Control of Viral Replication
Philip Mudd,
University of Wisconsin - Madison, USA
Reduction of CD4+ T Cells in vivo does not affect Virus Load in Macaque Elite Controllers
Reduction of CD4+ T Cells in vivo does not affect Virus Load in Macaque Elite Controllers
Pamela J. Skinner,
University of Minnesota, USA
Location, Abundance, and Activation/Proliferation Status of SIV-Specific CD8 T Cells in situ in SIVdeltanef Immunized SIVmac251 Challenged Rhesus Macaques
Location, Abundance, and Activation/Proliferation Status of SIV-Specific CD8 T Cells in situ in SIVdeltanef Immunized SIVmac251 Challenged Rhesus Macaques
17:00—19:00
Targeting Mucosal and T Cell Immunity (Joint)
James B. Whitney,
Beth Israel Deaconess Medical Center, Harvard University, USA
Short Talk: Reduction of Founder/Transmitted Virus in Vaccinated Monkeys after Mucosal SIV Challenge
Short Talk: Reduction of Founder/Transmitted Virus in Vaccinated Monkeys after Mucosal SIV Challenge
Robin Shattock,
Imperial College London, UK
Combining Prevention Technologies: Vaccines and Microbicides
Combining Prevention Technologies: Vaccines and Microbicides
Mario Roederer,
NIAID, National Institutes of Health, USA
Identification and Characterization of T Memory Stem Cells in Humans and NHP: Implication for Vaccine Design
Identification and Characterization of T Memory Stem Cells in Humans and NHP: Implication for Vaccine Design
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
